Given that there is a selective specific Aurora B kinase inhibitor available—AZD1152 (barasertib), which is currently in the clinical phase II stage for the inhibition of the proliferation of various cancers, including leukemia and some solid tumors [4, 9]—we assessed the inhibitory effect of this inhibitor on gastric cancer cells. Here, AURKB is linked to cancer.